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‘Test, re-test, re-test’: using inaccurate tests 
to greatly increase the accuracy of COVID-19 
testing
To the Editor — Commenting recently on 
rapid point-of-care tests, US COVID-19 
coordinator Deborah Birx said, “We are  
very quality-oriented. We don’t want  
false positives.”1
“If they are incredibly accurate, we will 
work out the quickest way to release them.  
If they are not accurate, we will not release 
any of them.” echoed UK Chief Medical 
Officer Chris Whitty2.
Given the need for testing3, the end goal 
is a quick, accurate and cheap test. With 
scientific innovation, we will, in time, attain 
this goal. But the best is becoming the 
enemy of the good. Meanwhile, avoidable 
infections are growing.
The ‘gold standard’ RT-PCR test 
for COVID-19 is highly accurate and 
reproducible, but is costly (US$125 per  
test kit, and over $15,000 to set up a 
processing lab) and slow (4–6 hours of 
processing time, and a turnaround of  
2–4 days, including shipping)4.
At the other extreme, a Bangladeshi  
lab has reportedly developed a $3 rapid test 
kit that gives a result in under 15 minutes  
(ref. 4). But the accuracy of such 
point-of-care tests is questionable.
Smart tactics can help break this tradeoff 
between cost and quality.
First, consider two quick, cheap and 
inaccurate tests, each developed by a 
different lab, and based on detection of 
a different antibody — or of the same 
antibody, but via a different method. 
Suppose each test has a false-negative  
rate of 30%, and, for simplicity, zero 
false-positive results. What if both tests  
were administered to the same person?  
If the results of the two tests are 
independent, the chances of obtaining  
two false-negative results drops to 9%  
(and to less than 3% if a third independent 
test with similar characteristics is 
administered). Figure 1 illustrates this 
logic, which also applies to false-positive 
results, for a test with a 50% false-negative 
rate. (Reports suggest that the tests being 
considered for large-scale procurement 
in the UK are in this range4,5). As a 
comparison, since 2017, rapid influenza 
diagnostic tests cleared by the US Food 
and Drug Administration have been 
required to achieve false-negative rates and 
false-positive rates of below 20% and 5%, 
respectively, compared with RT-PCR6.
Second, this recommendation to test and 
re-test can apply elsewhere too. Consider a 
test that displays the same false-negative  
and false-positive rates as the tests  
above — and is also unreproducible.  
If a patient is tested twice in succession 
with this test, the results could 
vary. Counterintuitively, this lack of 
reproducibility may be advantageous. 
Again, if the results of the two tests 
are independent, the likelihood of two 
false-negative results drops to 9%.
The implication is clear: even an 
inaccurate test tells us something. Or, to 
misquote the World Health Organization: 
‘test, re-test, re-test’.
Use of this strategy would be made 
easier if there were a database — updated 
in real time — of point-of-care tests being 
generated by labs around the world. This 
database, which could be assembled by an 
international organization such as the World 
Health Organization, would list the lab and 
test name, the antibody that the test detects 
(e.g., IgG, IgN or both7), the detection 
method (e.g., lateral-flow immunoassay) 
and its accuracy and reproducibility, the 
turnaround time, the testing-kit cost and 
the sample-processing cost. With this 
information in hand, governments and 
international organizations could advise 
scientists on what combination of cheap 
tests would be optimal for specific nations.
Third, consider a quick and cheap test 
with a 30% false-positive rate, and for 
simplicity, zero false-negative results. First, 
one could test many people with this test, 
and then test the subset who test positive 
with a highly accurate test. This economizes 
on the use of scarce but accurate test kits 
while allowing much wider testing than 
would have been possible with the few 
accurate test kits available. In short: ‘test, 
triage, re-test’.
Finally, smart tactics can enable cheaper 
testing with the expensive RT-PCR tests, 
if a sample obtained can ‘fuel’ multiple 
tests. Some German hospitals are doing 
‘block tests’ using a sample pooled from ten 
employees, and then are testing individually 
only if there is a positive result8.
One can take this idea further, 
by applying principles from discrete 
optimization. If the test is positive, then 
one would test two blocks of five samples 
each, and then further test the arm that tests 
positive. This mimics ‘branch and bound’ 
algorithms for solving discrete optimization 
problems such as the famous ‘traveling 
salesperson’ problem9, which requires 
finding the cheapest route for delivering 
supplies to a fixed number of stores.
These simple examples are illustrative. 
Naturally, several factors would come 
into play in their implementation. For 
example, block testing would increase time 
to diagnosis and may be more useful for 
asymptomatic low-risk cases.
Finally, all inaccuracies are not equal. 
Right now, tests with a high false-positive 
rate are less problematic — since  
people are being advised to stay home 
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Fig. 1 | Why re-testing increases testing accuracy.
Nature MediciNe | www.nature.com/naturemedicine
correspondence
anyway — than those with high 
false-negative rates. Furthermore, a 
false-positive result for SARS-CoV-2 is 
unlikely to initiate treatment with negative 
side effects, as would chemotherapy for 
misdiagnosed cancer.
The key point here is that creative use 
of currently available cheap and quick 
tests — even if they are inaccurate and 
unreproducible — can go a long way to 
reaching adequate levels of accuracy and 
precision, at least until the gold-standard 
tests can be developed. ❐
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